Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
InxMed 2026 Company Profile: Valuation, Funding & Investors | PitchBook
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 ...
Jointly Developed Antibody Drug INES103 by Escugen and InxMed Receives ...
InxMed Secures HK$100 M Private Placement from TruMed Health - Insight ...
Inxmed - 2026 Company Profile, Team, Funding & Competitors - Tracxn
InxMed Announces Promising Phase Ib/II Clinical Data for Ifebemtinib ...
InxMed Closes ￥130M Series A+ Round of Financing-动脉网
GeneQuantum and InxMed have reached a technology licensing ...
Inxmed has announced two sets of data on FAK inhibitor Ifebemtinib
InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients ...
Pre-IPO InxMed - The Pipeline and the Outlook - Xinyao (Criss) Wang
Inxmed (Nanjing) Co., Ltd (应世生物科技（南京）有限公司) - 药物管线_专利_临床试验_投融营收_最新药物:格索雷 ...
InxMed raises funding to advance new cancer therapies
InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ ...
Genequantum licenses conjugation technology to Inxmed for ADC ...
Inxmed (Shanghai) Co., Ltd - Drug pipelines, Patents, Clinical trials ...
James McLeod - Chief Medical Officer, USA at InxMed | The Org
InxMed Secures USD 34m to Develop Solid Tumour Resistance Therapies
InxMed Licenses Next-Gen ADCs with Escugen
Fei Cao - COO at InxMed | The Org
Ennovation Ventures Portfolio | InxMed Linited's Ifebemtinib: Included ...
InxMed Receives $10M Debt Financing from SPD Silicon Valley Bank to ...
Fei Cao - Co-founder & COO at InxMed | The Org
Brianna Han - InxMed 应世生物 | 领英
Yanan Liu - Senior Director, Project Management at InxMed | The Org
Startup
Metric Design Studio - an integrated digital design agency in Shanghai
应世生物科技（上海）有限公司 - 企查查
应世生物 InxMed-B，递交IPO招股书，拟赴香港上市，中信证券、建银国际联席保荐_腾讯新闻
应世生物62岁CEO王在琪是海归博士、年薪190万，曾任职美国先灵葆雅_中金在线财经号
晶存科技、坦博尔、纳真科技、滨会生物、应世生物等5家香港上市备案补充 (截至1128)_腾讯新闻
InxMed's Ifebemtinib Earns Breakthrough Therapy Designation for NSCLC ...
InxMed-Biotech_Pipeline_FAK inhibitor_Biological R&D
InxMed-Leading Innovations Targeting Tumor Defense
应世生物旗下IN10018与Cobimetinib达成全球联合用药临床合作_应世生物_FAK抑制剂IN10018_抗肿瘤创新生物药
#asco2025 #oncologyleadership #biotechnetworking #locustwalk #inxmed # ...
InxMed's IN10018 Receives U.S. FDA Fast Track Designation
36岁考博，从医院到Biotech！谢爽：我是新药研发的“泥石流” - 知乎
应世生物与华奥泰宣布达成联合研发战略合作-应世生物
全球创新_应世生物_FAK抑制剂IN10018_抗肿瘤创新生物药
INXMED港股招股书失效，公司为临床后期阶段生物科技企业 | 新时空
写意人物丨王在琪：研发具有全球影响力的个体化治疗药物_中国
Interviews Archive
HKSTP Brings Together Life and Health Tech Leaders at CTC Marketplace ...
Zaiqi Wang - Chairman & CEO, InxMed, China
中国InxMed社、FAK阻害薬とKRAS G12C阻害薬を併用した臨床試験のデータを報告：日経バイオテクONLINE
应世生物团队在iScience发表Ifebemtinib联用ADC协同增效治疗肿瘤研究-应世生物
Chinese startups provide strong support for innovative ADC drug R&D
加入我们_应世生物_FAK抑制剂IN10018_抗肿瘤创新生物药
Francis Cao - Crunchbase Person Profile
Lepu Moves Pancreatic Cancer ADC to Phase III
今日，6款创新药物拟纳入突破性疗法医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Hengrui's SHR2554 Becomes China's First Approved EZH2 Inhibitor
王在琪博士受邀访问UCSD并发表转化医学主题讲座-应世生物
应世生物陷双重困境：7 年累计亏超 8 亿，员工架构与费用披露矛盾待解｜IPO观察__财经头条
应世生物赴港IPO：核心产品或成中国首个获批的选择性FAK抑制剂 聚焦于FAK，打造起多功能产品组合以满足巨大的未满足医疗需求。据IPO早知道 ...
互扬医药猎头公司
Sanofi's Rilzabrutinib Is First BTKi for Immune Thrombocytopaenia
Joyo starts its first pivotal trial | ApexOnco - Clinical Trials news ...
(Ifebemtinib)-药物靶点：FAK_在研适应症：铂耐药性卵巢癌，卵巢癌，输卵管癌_专利_临床_研发
Benethera Receives IND Clearance in US for First-in-Class Oral Treg Inducer
622P Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 ...
一线非小细胞肺癌突破，应世生物Ifebemtinib再度纳入突破性治疗品种医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Antibody-drug Conjugate Information | ADCdb
RemeGen's Telitacicept Meets the Mark in IgA Nephropathy Trial
应世生物再冲IPO，手握国内唯一III期FAK抑制剂_财经频道_中华网
IPO研究｜中国首个选择性FAK抑制剂预计2026年获批，到2035年市场规模15.7亿美元_复合_治疗_全球
应世生物冲刺港股：年亏损1.85亿 刚融资3370万美元 估值3亿美元 雷递网 雷建平 9月9日应世生物（InxMed Limited）日前 ...
应世生物IPO：62岁医学博士掌舵，复星医药、刘永好助力
应世生物冲刺港股：年亏损1.85亿 刚完成3370万美元融资 估值3亿美元 雷递网 雷建平 9月9日 应世生物（InxMed Limited ...
应世生物递表港交所，致力于改进目前疗效有限的肿瘤治疗方案 | 星岛环球网
FAK抑制剂研发公司「应世生物-B」首次递表，最快年底申请NDA 来源：招股书来源|LiveReport大数据招股书|点击文末“阅读原文 ...
应世生物IPO：研发大砍，靠一款预备商业化产品来撑门面，资本会买账吗？ 文 | 医药研究社 复星医药 押注的一家创新药企终于开启了IPO征程 ...
上海诗健生物科技有限公司
Targeting FAK improves the tumor uptake of antibody-drug conjugates to ...
AbbVie Gains US Full Approval for Epcoritamab in Follicular Lymphoma
应世生物与启德医药达成技术授权合作，深度推进创新ADC药物研发-应世生物
